• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Cardiology

Asundexian inferior to apixaban as anticoagulation therapy for atrial fibrillation

byNhat Hung (Benjamin) LamandKiera Liblik
August 29, 2026
in Cardiology, Chronic Disease
Reading Time: 3 mins read
Atrial fibrillation collage: an engraved heart, a hovering hummingbird and a teal ribbon that goes from jagged to smooth
Share on FacebookShare on TwitterShare on LinkedIn

1. In this randomized controlled trial, among patients with atrial fibrillation requiring anticoagulation therapy, asundexian resulted in a high risk of stroke or systemic embolism compared to apixaban.

2. Although there was lower bleeding risk with asundexian, the study was stopped prematurely for lack of efficacy.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Atrial fibrillation is a common cardiac arrhythmia, which can cause thromboembolic events and result in high risks of disability and death. Anticoagulation is indicated to prevent thromboembolism and direct-acting oral anticoagulants (DOACs) are the preferred agents with established safety and efficacy. Nevertheless, DOACs are also associated with an increased risk of bleeding, limiting their use in certain patients. Asundexian, an oral-activated factor XI inhibitor, is associated with lower bleeding risk than apixaban but its efficacy remains unclear. This trial compared asundexian against apixaban in patients with atrial fibrillation and indicated for anticoagulation. Asundexian was found to result in more stroke or systemic embolism than apixaban during the interim analysis. Although asundexian was also associated with fewer major bleeding events, the trial was stopped prematurely due to lack of efficacy. The study was limited by its early termination, unclear generalizability to the general patient population with atrial fibrillation, and inclusion of only one dosage of asundexian. Overall, these results showed that asundexian at 50mg once daily resulted in a higher risk of stroke and systemic embolism compared to apixaban.

Click here to read the study in the NEJM (New England Journal of Medicine)

Drug pageSunharbo (asundexian), approved Nov 9, 2026. Indication, pivotal trial and safety at a glance.→

In-Depth [randomized controlled trial]: This study was a phase three, double-blind, randomized, controlled trial comparing the efficacy and safety of asundexian against apixaban for the prevention of stroke or systemic embolism. Patients 18 years of age or older, who had atrial fibrillation with an indication for indefinite anticoagulation and met various CHA2DS2-VASc thresholds depending on their specific gender, age, renal function, and history of previous thromboembolic events and nontraumatic major bleeding, were eligible for inclusion. Exclusion criteria included mechanical heart valve, reversible atrial fibrillation, recent ischemic stroke, active bleeding, severe renal or hepatic insufficiency, and indication for anticoagulation other than atrial fibrillation. In total, 14,810 patients were randomized 1:1 to receive asundexian 50mg once daily or standard-dose apixaban. The primary efficacy outcome was stroke or systemic embolism. The primary safety outcome was major bleeding. The mean age (±SD) of included patients was 73.9±7.7 years and the mean CHA2DS2-VASc score was 4.3±1.3. Between December 2022 and November 2023, stroke or systemic embolism occurred in 98 patients (1.3%) in the asundexian group and 26 (0.4%) in the apixaban group (hazard ratio [HR] 3.79, 95% confidence interval [CI] 2.46-5.83). The incidences of death from any cause (HR 0.84, 95% CI 0.60-1.19) and death from cardiovascular causes (HR 1.09, 95% CI 0.72-1.64) were similar between the two groups. The study was terminated prematurely due to lack of efficacy. Major bleeding occurred in 0.2% of patients in the asundexian group and 0.7% in the apixaban group (HR 0.32, 95% CI 0.18-0.55). The rates of any adverse events, overall, were comparable between the two groups. In summary, these results showed that asundexian at 50mg once daily was inferior to apixaban in preventing stroke or embolic events in patients with atrial fibrillation.

RELATED REPORTS

Asundexian reduced ischemic stroke risk by 26% after recent non-cardioembolic stroke or high-risk transient ischemic attack

Frailty in older adults with atrial fibrillation is multifactorial and associated with metabolic and cognitive factors

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: #cardiologyapixabanasundexianatrial fibrillationchronic disease
Previous Post

Levofloxacin shows limited efficacy in preventing multidrug-resistant tuberculosis

Next Post

Avian Influenza A(H5N1) caused mild illness in the exposed U.S. population

RelatedReports

TIA collage: a calm older man, a neck artery traced by a teal ribbon, an hourglass and folded reading glasses
2MM Trial Briefs

Asundexian reduced ischemic stroke risk by 26% after recent non-cardioembolic stroke or high-risk transient ischemic attack

November 10, 2026
An anatomical illustration of a heart with an electrocardiogram line and a catheter, indicating atrial fibrillation ablation procedures.
Cardiology

Frailty in older adults with atrial fibrillation is multifactorial and associated with metabolic and cognitive factors

September 30, 2026
A man is sleeping on his side with a caution symbol and tape beside him, while lung images are in the background, suggesting a focus on sleep and respiratory health.
Cardiology

Increased rapid eye movement (REM) sleep is associated with lower risks of several chronic diseases

September 23, 2026
A detailed illustration of a kidney and glomeruli, with a pill depicted, representing treatment for kidney-related conditions. It suggests a focus on chronic kidney disease.
Nephrology

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

September 9, 2026
Next Post
Hypotonic IVF linked to increased risk of hyponatremia

Avian Influenza A(H5N1) caused mild illness in the exposed U.S. population

Liver cancer immunotherapy collage: an engraved liver and gallbladder with round immune cells at its edge and a potted fern

Transarterial chemoembolization with pembrolizumab and levatinib improves survival in unresectable hepatocellular carcinoma

Neuroendocrine tumor treatment collage: a calm freckled woman beside a wooden hourglass and a round white tablet

Cabozantinib significantly improves progression free survival in patients with advanced neuroendocrine tumors

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Inhaled corticosteroids do not improve outcomes in sickle cell disease patients without asthma
  • Interim global phase 2 AZUR-1 results show durable responses with dostarlimab monotherapy in untreated MSI-H/dMMR stage II/III locally advanced rectal cancer
  • AI health chatbot shows no benefit for perinatal anxiety or depression
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.